ASX 200 morning report – BLD, SVW & CHC shares in focus
Drew Meredith, CFP
June 28, 2021
The S&P/ASX 200 (ASX: XJO) delivered another strong day on
Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
The S&P/ASX 200 (ASX: XJO) delivered another strong day on
The S&P/ASX 200 (INDEXASX:XJO) finished at an all-time high on
The Mesoblast Limited (ASX:MSB) share price is under the spotlight
The Mesoblast Limited (ASX: MSB) share price jumped as high
The Mesoblast Limited (ASX:MSB) share price is under scrutiny today
The Mesoblast Limited (ASX:MSB) share price will be on watch
The Mesoblast Limited (ASX:MSB) share price is up 5% after
The Mesoblast Limited (ASX:MSB) share price is going nuts again
The S&P/ASX 200 (INDEXASX:XJO) is set to open higher on
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.